Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726020 | SCV000341275 | pathogenic | not provided | 2016-04-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000022052 | SCV000798041 | uncertain significance | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2018-02-20 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000022052 | SCV000938537 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2022-01-18 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects GALT function (PMID: 22461411, 25592817). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function. ClinVar contains an entry for this variant (Variation ID: 25125). This missense change has been observed in individual(s) with classic galactosemia (PMID: 22461411, 25592817). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 34 of the GALT protein (p.Tyr34Asn). |
Mendelics | RCV000022052 | SCV001137801 | pathogenic | Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase | 2019-05-28 | criteria provided, single submitter | clinical testing |